BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30545446)

  • 1. Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy.
    Batzner A; Pfeiffer B; Neugebauer A; Aicha D; Blank C; Seggewiss H
    J Am Coll Cardiol; 2018 Dec; 72(24):3087-3094. PubMed ID: 30545446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
    Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S
    J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term outcome of patients with hypertrophic obstructive cardiomyopathy post percutaneous transluminal septal ablation].
    Zheng SW; Shi HY; Dai JJ; Chen H; Wu WH; Qiu XB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):294-301. PubMed ID: 32370480
    [No Abstract]   [Full Text] [Related]  

  • 4. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients.
    Faber L; Meissner A; Ziemssen P; Seggewiss H
    Heart; 2000 Mar; 83(3):326-31. PubMed ID: 10677415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.
    Seggewiss H; Rigopoulos A; Welge D; Ziemssen P; Faber L
    Clin Res Cardiol; 2007 Dec; 96(12):856-63. PubMed ID: 17891517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.
    Rigopoulos AG; Daci S; Pfeiffer B; Papadopoulou K; Neugebauer A; Seggewiss H
    Clin Res Cardiol; 2016 Nov; 105(11):953-961. PubMed ID: 27270758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.
    Kuhn H; Lawrenz T; Lieder F; Leuner C; Strunk-Mueller C; Obergassel L; Bartelsmeier M; Stellbrink C
    Clin Res Cardiol; 2008 Apr; 97(4):234-43. PubMed ID: 18071624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography].
    Faber L; Seggewiss H; Fassbender D; Bogunovic N; Strick S; Schmidt HK; Gleichmann U
    Z Kardiol; 1998 Mar; 87(3):191-201. PubMed ID: 9586154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.
    Alam M; Dokainish H; Lakkis N
    J Interv Cardiol; 2006 Aug; 19(4):319-27. PubMed ID: 16881978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients.
    Guo H; Wang J; Chen J; Shan J; Lee JD; Ueda T
    Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
    Seggewiss H; Faber L; Gleichmann U
    Thorac Cardiovasc Surg; 1999 Apr; 47(2):94-100. PubMed ID: 10363608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery.
    Qin JX; Shiota T; Lever HM; Kapadia SR; Sitges M; Rubin DN; Bauer F; Greenberg NL; Agler DA; Drinko JK; Martin M; Tuzcu EM; Smedira NG; Lytle B; Thomas JD
    J Am Coll Cardiol; 2001 Dec; 38(7):1994-2000. PubMed ID: 11738306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.
    Faber L; Welge D; Fassbender D; Schmidt HK; Horstkotte D; Seggewiss H
    Clin Res Cardiol; 2007 Dec; 96(12):864-73. PubMed ID: 17891518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy.
    Fortunato de Cano S; Nicolas Cano M; de Ribamar Costa J; Alves Pinheiro J; Bellio de Mattos Barretto R; Costa de Souza Le Bihan D; Abizaid A; Sousa A; Eduardo Sousa J
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):953-960. PubMed ID: 27143093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy - 8 years follow up.
    Sathyamurthy I; Nayak R; Oomman A; Subramanyan K; Kalarical MS; Mao R; Ramachandran P
    Indian Heart J; 2014; 66(1):57-63. PubMed ID: 24581097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Tsuchikane E; Takeda Y; Kobayashi T; Yachiku K; Nasu K; Kobayashi Y; Matsumoto H; Awata N
    Circ J; 2003 Sep; 67(9):763-7. PubMed ID: 12939552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Sorajja P; Valeti U; Nishimura RA; Ommen SR; Rihal CS; Gersh BJ; Hodge DO; Schaff HV; Holmes DR
    Circulation; 2008 Jul; 118(2):131-9. PubMed ID: 18591440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy.
    Burghardt A; van Buuren F; Dimitriadis Z; GrĂ¼bbel T; Seggewiss H; Scholtz S; Horstkotte D; Faber L
    Clin Res Cardiol; 2018 Jun; 107(6):479-486. PubMed ID: 29453593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results.
    Oomman A; Ramachandran P; Subramanyan K; Kalarickal MS; Osman MN
    J Invasive Cardiol; 2001 Jul; 13(7):526-30. PubMed ID: 11435640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.